SLRN ACELYRIN Inc.: Enterprise Value to EBITDA Ratio
Acelyrin, Inc. (SLRN) maintains a high reputation for developing advanced treatments for severe immune pathologies due to the success of its antibodies. The price trend reflected below with the indicator is linked to a lack of consistent profit, as financial stability depends on test outcomes. The business relies on an extensive network of external laboratories, which mitigates the risk of disruptions during early-stage trials.
Comprehensive metric breakdowns and analytics for acelyrin.com (SLRN)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
SLRN - Company Net Income|Future Profit Acelyrin, Inc.|SLRN - Market Cap to Earnings|Future Price to Earnings Acelyrin, Inc.|SLRN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple ACELYRIN Inc.|SLRN - Operating income before deduction of amortization|Earnings per share for the last twelve months ACELYRIN|SLRN - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months acelyrin.com|SLRN - Earnings per share increase in current year|Earnings growth forecast for next year Acelyrin, Inc.
Fundamental company analysis:ACELYRIN, Inc. SLRN
This indicator determines the business's ability to service its obligations and maintain resilience amid operating profit volatility. The dynamics of the EV/EBITDA ratio, accounting for financial leverage, allow investors to identify hidden cost-push inflation pressure on the total enterprise value. Calculated levels are formed by the balance of debt and cost efficiency, which is critical for Acelyrin, Inc. (SLRN) due to high expenses associated with retaining elite immunologists and costly stock option programs.
Competitors of Acelyrin, Inc. (SLRN)
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|EV/EBITDA Multiple MannKind Corp MNKD|Amphastar - EV/EBITDA Multiple|Pacira Corp (PCRX) - Enterprise Value to EBITDA Ratio|SPRY: EV/EBITDA Multiple|Company Value to EBITDA theravance.com (TBPH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SCPH|Enterprise Value to EBITDA Ratio TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|Business Value to Operating Income Before Depreciation EPRX|BioHarvest Sciences Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Invizyne Technologies EXOZ|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ENTX|Enterprise Value to EBITDA Ratio HYFT|ABVC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPIX|Total Company Value to Operating Income Before Depreciation Ratio Quantum BioPharma Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen Corp FGEN|TELO: Enterprise Value to Operating Income Before Depreciation|Rani Therapeutics Inc - EV/EBITDA Multiple|Synergy CHC Corp (SNYR) - Enterprise Value to EBITDA Ratio|RLYB (rallybio.com) - Enterprise Value to EBITDA Ratio|LEXX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pulmatrix Corp|Pheton (PTHL) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptorum Group Limited (APM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LYRA (lyratherapeutics.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Impact BioMedical IBO|Business Value to Operating Income Before Depreciation TNFA|YCBD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRFX (PainReform Corp) - Enterprise Value to Operating Income Before Depreciation|altamiratherapeutics.com (CYTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LIPO (lipella.com)|OPTN (OptiNose) - EV/EBITDA Multiple|PIRS: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PROC|EV/EBITDA Multiple Petros Pharma (PTPI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Qilian International QLI|Business Value to Operating Income Before Depreciation TFFP
